These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1081153)

  • 1. [Lymphocyte transformation by melanin antigens in vitiligo vulgaris and malignant melanoma (author's transl)].
    Yamada M; Fujimoto F; Higashi K; Yanase K; Oku T
    Nihon Hifuka Gakkai Zasshi; 1975 May; 85(6):351-8. PubMed ID: 1081153
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vitiligo and malignant melanoma (author's transl)].
    Hamm G; Fiedler H
    Dermatol Monatsschr; 1979 Dec; 165(12):838-42. PubMed ID: 546664
    [No Abstract]   [Full Text] [Related]  

  • 3. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells].
    Höfs T
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo.
    Dorđić M; Matić IZ; Filipović-Lješković I; Džodić R; Sašić M; Erić-Nikolić A; Vuletić A; Kolundžija B; Damjanović A; Grozdanić N; Nikolić S; Pralica J; Dobrosavljević D; Rašković S; Andrejević S; Juranić Z
    BMC Complement Altern Med; 2012 Jul; 12():109. PubMed ID: 22834951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune vitiligo: detection of antibodies to melanin-producing cells.
    Hertz KC; Gazze LA; Kirkpatrick CH; Katz SI
    N Engl J Med; 1977 Sep; 297(12):634-7. PubMed ID: 331108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitiligo and malignant melanoma.
    Fodor J; Bodrogi I
    Neoplasma; 1975; 22(4):445-8. PubMed ID: 1196428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Spontaneous regression and leukoderma in malignant melanoma].
    Happle R; Schotola I; Macher E
    Hautarzt; 1975 Mar; 26(3):120-3. PubMed ID: 1126845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antimelanin antibodies in vitiligo].
    Vignale RA; Lasalvia E; Borras A
    Med Cutan Ibero Lat Am; 1983; 11(4):271-6. PubMed ID: 6355705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
    Cui J; Bystryn JC
    Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
    Ram M; Shoenfeld Y
    Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimelanoma immunity in vitiligo and melanoma patients.
    Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
    Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro lymphocyte stimulation by a soluble antigen from malignant melanoma.
    Jehn UW; Nathanson L; Schwartz RS; Skinner M
    N Engl J Med; 1970 Aug; 283(7):329-33. PubMed ID: 4193645
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum anti-tumour antibodies and auto-antibodies in vitiligo.
    Woolfson H; Finn OA; Mackie RM; McQueen A; MacSween RN
    Br J Dermatol; 1975 Apr; 92(4):395-400. PubMed ID: 1156553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
    Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
    Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant melanin granules in vitiliginous achromia with malignant melanoma.
    Ortonne JP; Perrot H
    Acta Derm Venereol; 1978; 58(6):475-80. PubMed ID: 83067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo.
    Onsun N; Büyükbabani N; Ummetoğlu O; Cebeci F
    J Dermatol; 2009 Nov; 36(11):612-5. PubMed ID: 19878396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Histocompatible antigens in vitiligo vulgaris II (author's transl)].
    Nakagawa H; Otuka F; Kukita A; Mizoguchi M; Ito H; Juji T
    Nihon Hifuka Gakkai Zasshi; 1980 Sep; 90(10):939-41. PubMed ID: 6971344
    [No Abstract]   [Full Text] [Related]  

  • 19. [Development of micro-culture technique of in vitro lymphocyte transformation and its application to the various skin diseases (author's transl)].
    Kanaide A
    Nihon Hifuka Gakkai Zasshi; 1977 Jul; 87(8):469-86. PubMed ID: 333146
    [No Abstract]   [Full Text] [Related]  

  • 20. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
    Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
    Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.